Full Press Release Details
NewcelX Appoints Dr. Julien Boisdron, a Swiss
in Diabetes Innovation, to Its Scientific Advisory Board
Zurich, Switzerland and Ness Ziona, Israel - January 5th, 2026 - NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX"), a biotechnology
company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment
of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific
Advisory Board ("SAB").
Dr. Boisdron brings more than two decades of
global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap
pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and
real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the
integration of therapeutic and digital solutions to enhance patient outcomes.
In joining the NewcelX SAB, Dr. Boisdron
will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program a
stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Type 1 Diabetes represents the Company's primary
clinical focus, and Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration,
and future global commercialization frameworks.
"I am honored to join NewCelX's Scientific Advisory Board
and to collaborate on advancing next-generation therapies for diabetes," said Dr. Boisdron. "NewCelX's integrated
platform, combining cell-therapy and neuroscience innovation, offers a compelling foundation to move potentially transformative treatments
closer to patients."
"Welcoming Dr. Boisdron to our advisory board strengthens NewCelX's
leadership in metabolic and regenerative medicine," said Prof. Michel Revel, Chief Scientific Officer of NewCelX. "His
extensive experience in diabetes care and global medical leadership will enrich our strategic direction as we advance our IsletRx program."
"Type 1 Diabetes is the core focus of NewcelX and a key priority
in our clinical development strategy," said Ronen Twito, Executive Chairman & CEO of NewcelX. "As we advance our
IsletRx program toward the clinic, Dr. Boisdron's deep experience in diabetes innovation, clinical strategy, and global healthcare
systems will be highly relevant to our efforts. His perspective strengthens our ability to develop a cell-based therapy designed to address
the needs of patients with insulin-dependent diabetes."
NewCelX Ltd. (Nasdaq: NCEL) is a biotechnology
company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's
integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments
targeting conditions such as ALS and Type 1 Diabetes. NewCelX is headquartered in Zurich, Switzerland, with research and development
operations in Ness Ziona, Israel.
Forward-Looking Statements
This press release contains expressed or implied
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities
laws. For example, NewcelX is using forward-looking statements when it discusses the anticipated contributions of Dr. Julien Boisdron,
MD and the potential of NewcelX to deliver a functional cell-based solution for insulin-dependent diabetes. These forward-looking statements
and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology
and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by
regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract
key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory
that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays
in developing or introducing new technologies, products, or applications; and competitive pressures that could reduce market share or
pricing. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in its Annual
Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission ("SEC") and
available at www.sec.gov, as well as in subsequent filings made by NewcelX, including under the heading "Risk Factors"
in its proxy statement/prospectus filed with the SEC on November 6, 2025.
Investor & Media Contacts
Sarah Bazak, Investors relations
Social Media: LinkedIn, X, Facebook, Instagram